Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by Mole101on Aug 23, 2021 11:31am
105 Views
Post# 33748390

Antibody testing is coming , it’s just a matter of when…

Antibody testing is coming , it’s just a matter of when…

The UK government is set to launch a nationwide antibody surveillance programme, making free home antibody tests available for up to 8,000 Covid-19-positive people per day. The UK Health Security Agency will provide finger- tests to gain more insights into immunity against Covid-19 from vaccination and infection. Individuals aged above 18 years can opt-in to be part of the programme when booking a PCR test for Covid-19 via NHS Test and Trace service.

 

Israel has rolled out antibody testing for children aged as young as three years to obtain data on the number of youths who did not receive a Covid-19 vaccine but developed protection against the disease through infection. Vaccination of children aged 12 years and older is currently underway in the country. The new serological survey targets about 1.5 million children aged three to 12 years who are currently ineligible for a vaccine. Children found to have adequate antibodies will not be required to quarantine on exposure to a Covid-19 patient, which is intended to limit schoolyear disruptions.

 
<< Previous
Bullboard Posts
Next >>